PathAI's mission is to improve patient outcomes with AI-powered pathology. Our platform promises substantial improvements to the accuracy of diagnosis and the efficacy of treatment of diseases like cancer, leveraging modern approaches in machine learning. We are a company of diverse employees with a wide range of backgrounds and experiences. Our world class team is passionate about solving challenging problems and making a huge impact. Our office is located in the heart of Fenway. PathAI was recently voted one of BBJ's Best Places to Work!
PathAI的外部链接
PathAI转发了
Precision Medicine for Inflammation & Immunology | AI Product Portfolio & Scientific Strategy
Beyond proud of PathAI, our collaborators, partners and the patients who made EMA's full qualification of AIM-MASH AI Assist a reality #AIMforthestars #USCAP #AIpathology #MASH #clinicaltrials
PathAI转发了
Thrilled to share that PathAI’s AIM-MASH AI Assist has received qualification from the European Medicines Agency (EMA)—the first AI-powered tool qualified by EMA for diagnosing inflammatory liver disease (NASH) from biopsy samples. This is a significant milestone for PathAI and the role of AI powered pathology in drug development. Proud of our team’s work and tremendously grateful to all our collaborators, partners and patients who made this possible. From the EMA's statement (https://lnkd.in/e77HSetz): "CHMP?agreed that the tool can increase reproducibility and repeatability in assessments for new MASH treatments. It can help researchers obtain clearer evidence on the benefits of new treatments in?clinical trials?that include fewer patients. Ultimately, this can bring effective treatments to patients faster. Testing new MASH treatments often relies on liver biopsies, where small pieces of liver tissue are taken to confirm inflammation and scarring. These biopsies are the gold standard for demonstrating the efficacy of new, investigational medicines. However, high variability in MASH/NASH?clinical trials?is a challenge, as specialists who review biopsy samples may not always agree on the severity of inflammation or scarring. The evidence submitted to?CHMP?shows that AIM-NASH biopsy readings, verified by one expert pathologist, can reliably determine MASH disease activity with less variability than the current standard used in?clinical trials, which relies on a consensus by three independent pathologists."
?? Today, we are thrilled to announce that ??????-???????? ???? ???????????? has been granted full qualification by the EMA CHMP, European Medicines Agency—making it the first and only AI-assisted pathology tool qualified for #histology enrollment and endpoint assessment in #MASH #clinicaltrials This qualification marks one of the most significant milestones in #AIPathology, bringing these tools closer than ever to making a direct impact on patients living with MASH. ??? Read the #PressRelease: https://lnkd.in/eGpP_NT5 AIM-MASH AI Assist provides a standardized, scalable, and AI-powered approach to evaluating liver biopsies, enabling #pathologists to enhance the analysis of complex tissue samples and aid in scoring patient samples for critical, life-saving clinical trials for MASH—a disease affecting over 52 million people in Europe. ?? Why this matters: - First AI-assisted #pathology tool qualified by EMA for MASH trials - Enables histology-based enrollment and primary/secondary endpoint assessment - Supports single-central pathologist workflows, reducing variability and increasing efficiency - Fully validated, ensuring accurate and reliable assessments "This achievement underscores our commitment to leveraging AI to transform pathology and improve patient outcomes. We believe that AIM-MASH AI Assist will play a crucial role in advancing MASH research and bringing much-needed therapies to patients," said Andrew Beck, CEO of PathAI. ??????-???????? ???? ???????????? ???? ?????? ???????????????? ?????? ????????. ?????? ?????? ?????? ???? ???????????????????? ????????????????????
#ICYMI: ??????-???????? ???? ???????????? has been granted full qualification by the EMA CHMP, European Medicines Agency—making it the first AI-assisted #pathology tool qualified for #histology enrollment and endpoint assessment in #MASH #clinicaltrials Learn More: https://lnkd.in/eGpP_NT5 This qualification marks one of the most significant milestones in #AIPathology, bringing these tools closer than ever to making a direct impact on patients living with MASH.
PathAI转发了
EMA has qualified the first artificial intelligence tool, called AIM-NASH, which helps pathologists analyse liver biopsy scans to identify the severity of an inflammatory liver disease (MASH) in clinical trials. The tool is expected to help researchers obtain clearer evidence on the benefits of new treatments. The tool is trained on more than 100,000 annotations from 59 pathologists who assessed over 5,000 liver biopsies across nine large #clinicaltrials. This qualification marks a significant step towards integrating #AI in medicine development. Read more: https://lnkd.in/g_8BrEvn
PathAI转发了
This is a huge milestone for the AI-pathology industry, for the MASH clinical development field, and ultimately for patients. Congratulations to the entire PathAI team on the qualification of the first ever artificial intelligence drug development tool - AIM-NASH - by the European Medicines Agency.
EMA has qualified the first artificial intelligence tool, called AIM-NASH, which helps pathologists analyse liver biopsy scans to identify the severity of an inflammatory liver disease (MASH) in clinical trials. The tool is expected to help researchers obtain clearer evidence on the benefits of new treatments. The tool is trained on more than 100,000 annotations from 59 pathologists who assessed over 5,000 liver biopsies across nine large #clinicaltrials. This qualification marks a significant step towards integrating #AI in medicine development. Read more: https://lnkd.in/g_8BrEvn
?? Today, we are thrilled to announce that ??????-???????? ???? ???????????? has been granted full qualification by the EMA CHMP, European Medicines Agency—making it the first and only AI-assisted pathology tool qualified for #histology enrollment and endpoint assessment in #MASH #clinicaltrials This qualification marks one of the most significant milestones in #AIPathology, bringing these tools closer than ever to making a direct impact on patients living with MASH. ??? Read the #PressRelease: https://lnkd.in/eGpP_NT5 AIM-MASH AI Assist provides a standardized, scalable, and AI-powered approach to evaluating liver biopsies, enabling #pathologists to enhance the analysis of complex tissue samples and aid in scoring patient samples for critical, life-saving clinical trials for MASH—a disease affecting over 52 million people in Europe. ?? Why this matters: - First AI-assisted #pathology tool qualified by EMA for MASH trials - Enables histology-based enrollment and primary/secondary endpoint assessment - Supports single-central pathologist workflows, reducing variability and increasing efficiency - Fully validated, ensuring accurate and reliable assessments "This achievement underscores our commitment to leveraging AI to transform pathology and improve patient outcomes. We believe that AIM-MASH AI Assist will play a crucial role in advancing MASH research and bringing much-needed therapies to patients," said Andrew Beck, CEO of PathAI. ??????-???????? ???? ???????????? ???? ?????? ???????????????? ?????? ????????. ?????? ?????? ?????? ???? ???????????????????? ????????????????????
PathAI scientists published today “???????????????????????????? ???? ???????????????? ?????? ???????????????????? ???????????????? ???????? ??&??-?????????????? ?????????? ?????????? ?????????????????? ???????????? ???????????? ???????????? ?????????? ?????????? ?? ??????????????-?????????? ???????? ???????????????? ??????????” ?? Read the publication: https://lnkd.in/e5j-u9Vg ?? The search for novel #biomarkers for #oncology and #fibrosis has led to increased interest in studying collagen, because this structural element of the tumor microenvironment (#TME) contributes to cancer progression, metastasis, immune response, and drug resistance. Studying fibrosis and collagen fibers in cancer research is challenging because traditional methods are labor-intensive, require specialized stains and equipment, and are challenging to use at scale. In this paper, we detail the development of an #AIPathology tool, inferred quantitative multimodal anisotropy #imaging (iQMAI), designed to predict collagen in H&E-stained digital whole slide images. We show that collagen fibers can be extracted from iQMAI outputs, yielding quantitative insights about collagen fiber morphology. We also demonstrate the association between iQMAI-derived fiber features, immunosuppressive cancer-associated fibroblasts and overall survival in pancreatic cancer. #AI #digitalpathology #pancreaticcancer #fibrosis #cancer #cancerresearch #histopathology
?? The tides of transformation are coming to?#USCAP2025, and PathAI is making waves with AI-powered #digitalpathology!??? ??? ??? View our scientific program & connect with us at #USCAP:?https://lnkd.in/eNRnG389 ?? Oral Presentations: - Evaluation of an AI-powered digital #pathology tool for automated tumor detection and case prioritization - Quantitative Multimodal Anisotropy Imaging (QMAI) unveils and quantifies morphological collagen across multiple organ systems ?? Poster Presentations: - AI-Powered Automated Quality Control of Whole Slide Images by #ArtifactDetect Tool - AI-powered detection and classification of artifacts in whole-slide images of pathology specimens - Clinical Utility of Tumor-Detect AI Algorithm for Detection of #ProstateCancer on Transurethral Resection Specimens - AI-based triage of #dermatopathology specimens for #pathologist workload prioritization - ML-Enabled Pathological Features of Post-preoperative Therapy Surgical Specimens Improves Recurrence Prediction in Patients with Triple Negative #BreastCancer (TNBC) Treated with Neoadjuvant #Chemotherapy (NAC) ? Join us at Booth 412?for live demos and insights into the future of pathology. Don’t miss?H&E by the Sea, our exclusive waterfront reception on?March 25, 6-9 PM—request an invite today! ? #biotech #healthtech #AIPathology #CancerResearch #Oncology #Biomarker #IBD #UlcerativeColitis
As we get closer to #USCAP2025, we have our next blog in our series ?????? ?????????????? ?????????????????? ????????????????????????????: ?????????????? ?????????????????? ?????????????????????? ????????’?? ???????? ?????????? ????????—????’?? ?????????? ????????????, ?????? Ever heard the phrase “culture eats strategy for breakfast?” ?? That’s why investing in #digitalpathology goes beyond purchasing scanners, an IMS, and cloud storage. Moving from manual workflows to next-gen, #AI-enabled digital pathology requires the right people just as much as the right technology. Want to know the key hires every lab needs to make digital transformation a success? From scanner technicians to IT staff to change managers ?????? ???? ????????????, ????????????????????????!, people make all the difference. ?? Connect with us at #USCAP: https://lnkd.in/eNRnG389 #AIPathology #Pathology #Biotech #HealthTech #Histopathology
?? Connect with us at #USCAP2025. Be part of the Tides of Transformation—where #pathology meets the future ?? Visit our?booth?for live demos of AISight?, attend our?scientific programming, and network with #digitalpathology enthusiasts at our exclusive?H&E by the Sea?reception. ??? View our scientific program and request an invite: https://lnkd.in/eNRnG389 ??????????????? ???? ?????? ???????????????? ?????? ???????? ???? ?????? ????; ??????????????? ???? ???? ????-?????? ???????????? ???? ?????? ??????, ????, ?????? ??????????????????????. #USCAP #AI #biotech #histopathology
此处无法显示此内容
在领英 APP 中访问此内容等